Follow The Filings

CC Chemours Co.

Materials, filed as CHEMOURS CO (COM), Equity Among managers we track Quote on Google Finance, opens in a new tab

No current holdings among managers we track for this security. See ownership history or the ownership grid, activity, or search.

Insider trades

Open-market buys and sales by CC's executives, directors and 10% owners in the last 12 months, from their Form 4s

All CC insider trades
  • $489K bought by 7 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Calderon Gerardo Familiar See Remarks
    Buy
    $30K 1,935 shares at $15.53 +3.4% to stake
    Traded Aug 12 Filed Aug 13
    ↗
  2. Denise Dignam CEO
    Buy
    $51K 3,378 shares at $14.95 +1% to stake
    Traded Aug 11 Filed Aug 13
    ↗
  3. Alister Cowan Director
    Buy
    $203K 13,000 shares at $15.62 +30% to stake
    Traded Aug 7 Filed Aug 11
    ↗
  4. Michael Robert Foley See Remarks
    Buy
    $30K 1,934 shares at $15.51
    Traded Aug 7 Filed Aug 11
    ↗
  5. Joseph T. Martinko See Remarks
    Buy
    $30K 1,940 shares at $15.47 +3.6% to stake
    Traded Aug 7 Filed Aug 11
    ↗
  6. Mary B Cranston Director
    Buy
    $95K 6,000 shares at $15.83 +5.6% to stake
    Traded Aug 7 Filed Aug 11
    ↗
  7. Shane Hostetter CFO
    Buy
    $50K 3,350 shares at $14.94 +3.4% to stake
    Traded Aug 6 Filed Aug 10
    ↗

Also filed in the last 12 months, not counted as buying or selling: 20 stock grants and 14 share withholdings for taxes.

SEC filings

Recent issuer filings from EDGAR, 14 shown.

Filed Form Detail Links
8-K 1.01,7.01,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 1.01,7.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.02,5.07,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 1.01,2.03,8.01,9.01 Filing Doc
DEFA14A Filing Doc

Source: SEC EDGAR submissions, updated 15 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $6.03B $5.78B $5.81B
Gross profit $1.31B $1.15B $0.902B
Gross margin * 21.7% 19.9% 15.5%
Net income -$238M $86M -$386M
Net margin * -3.9% 1.5% -6.6%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $3.84B $3.03B $3B
Total non-current assets * $4.42B $4.49B $4.38B
Total assets $8.25B $7.52B $7.38B
Total current liabilities $1.74B $1.8B $1.67B
Total non-current liabilities * $5.45B $5.11B $5.14B
Total equity $737M $604M $566M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $556M -$633M $264M
Cash from investing -$229M -$353M -$206M
Cash from financing $172M -$36M -$126M
Net change in cash $0.503B -$1.04B -$0.039B

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf